PL2952197T3 - Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania - Google Patents

Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania

Info

Publication number: PL2952197T3
Authority: PL; Poland
Prior art keywords: sae; composition; preparation; methods; sulfoalkyl ether
Prior art date: 2005-10-26

Application number

PL15165737T

Other languages

English (en)

Inventor

Gerold L. Mosher

James D. Pipkin

Douglas B. Hecker

Original Assignee

Cydex Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2005-10-26

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37968086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2952197(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-26 Application filed by Cydex Pharmaceuticals, Inc. filed Critical Cydex Pharmaceuticals, Inc.

2017-09-29 Publication of PL2952197T3 publication Critical patent/PL2952197T3/pl

Links

239000000203 mixture Substances 0.000 title abstract 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
229920000858 Cyclodextrin Polymers 0.000 title 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
125000004964 sulfoalkyl group Chemical group 0.000 title 1
238000004090 dissolution Methods 0.000 abstract 1
230000000877 morphologic effect Effects 0.000 abstract 1
230000000704 physical effect Effects 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D1/00—Evaporating
- B01D1/16—Evaporating by spraying
- B01D1/18—Evaporating by spraying to obtain dry solids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Inorganic Chemistry (AREA)
Otolaryngology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

PL15165737T 2005-10-26 2005-10-26 Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania PL2952197T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2005/038933 WO2007050075A1 (en)	2005-10-26	2005-10-26	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

Publications (1)

Publication Number	Publication Date
PL2952197T3 true PL2952197T3 (pl)	2017-09-29

Family

ID=37968086

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL11161125T PL2335707T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
PL12189687T PL2583668T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
PL15165737T PL2952197T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
PL12189690T PL2581078T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL11161125T PL2335707T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
PL12189687T PL2583668T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL12189690T PL2581078T3 (pl)	2005-10-26	2005-10-26	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania

Country Status (21)

Country	Link
US (1)	US8049003B2 (pl)
EP (5)	EP2581078B1 (pl)
JP (1)	JP5465432B2 (pl)
KR (1)	KR101152886B1 (pl)
CN (1)	CN101365459B (pl)
AT (1)	ATE504305T1 (pl)
AU (1)	AU2005337613B2 (pl)
BR (1)	BRPI0520654B8 (pl)
CA (2)	CA2928065C (pl)
CY (3)	CY1116080T1 (pl)
DE (1)	DE602005027415D1 (pl)
DK (5)	DK1945228T4 (pl)
ES (5)	ES2542893T3 (pl)
HU (2)	HUE035181T2 (pl)
IL (3)	IL191081A (pl)
LT (1)	LT2952197T (pl)
MX (2)	MX383536B (pl)
PL (4)	PL2335707T3 (pl)
PT (5)	PT1945228E (pl)
SI (2)	SI2952197T1 (pl)
WO (1)	WO2007050075A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005061088A1 (en) *	2003-12-22	2005-07-07	Finlay Warren H	Powder formation by atmospheric spray-freeze drying
PL2708225T3 (pl) *	2004-04-23	2019-07-31	Cydex Pharmaceuticals, Inc.	Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2009018069A2 (en) *	2007-07-30	2009-02-05	Cydex Pharmaceuticals, Inc	Mixtures of cyclodextrin derivatives
US8501740B2 (en) *	2007-10-09	2013-08-06	Board Of Regents, The University Of Texas System	Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
US8492538B1 (en)	2009-06-04	2013-07-23	Jose R. Matos	Cyclodextrin derivative salts
KR101868117B1 (ko)	2010-08-05	2018-06-18	시가 테크놀로지스, 인크.	Ｓｔ246 액체 제형 및 방법
HUE037660T2 (hu)	2011-01-26	2018-09-28	Allergan Inc	Androgén készítmény szembetegség kezelésére
US8992987B2 (en)	2011-04-06	2015-03-31	Dow Global Technologies Llc	Polysaccharide derivatives and dosage forms
EP4083075A1 (en)	2012-02-15	2022-11-02	CyDex Pharmaceuticals, Inc.	Manufacturing process for cyclodextrin derivatives
HK1211311A1 (en) *	2012-02-28	2016-05-20	锡德克斯药物公司	Alkylated cyclodextrin compositions and processes for preparing and using the same
HK1213585A1 (zh)	2012-10-22	2016-07-08	Cydex Pharmaceuticals, Inc.	烷基化环糊精组合物及其制备和使用方法
MA38121A1 (fr) *	2012-11-30	2016-10-31	Glaxosmithkline Llc	Nouvelle composition pharmaceutique
PT3183295T (pt)	2014-08-22	2023-11-03	Cydex Pharmaceuticals Inc	Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
EP4620534A3 (en)	2015-03-19	2025-12-24	CyDex Pharmaceuticals, Inc.	Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
EP3097962B1 (de) *	2015-05-29	2020-05-13	Symrise AG	Vorrichtung zur herstellung von sprühgetrockneten agglomeraten
EP3525792A4 (en) *	2016-10-11	2020-04-22	Aucta Pharmaceuticals	POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN
US20180318249A1 (en)	2017-05-03	2018-11-08	Cydex Pharmaceuticals, Inc.	Composition containing cyclodextrin and busulfan
EP3906019B1 (en)	2019-01-04	2025-11-26	SQ Innovation AG	Pharmaceutical compositions of furosemide
EP3906020B1 (en)	2019-01-04	2025-12-31	SQ Innovation AG	Pharmaceutical compositions of torsemide and their uses
AU2020312165A1 (en) *	2019-07-09	2022-01-20	Basf Se	Tableting of specific polymer stabilizers
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
IL321589A (en)	2019-08-01	2025-08-01	Incarda Therapeutics Inc	Antiarrhythmic formulation comprising a salt of flecainide
US20230227506A1 (en)	2020-06-18	2023-07-20	The University Of Bristol	Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
WO2022029334A1 (en)	2020-08-07	2022-02-10	Gbiotech S.À.R.L.	Combination therapies for treating coronavirus infection
JP2024516464A (ja)	2021-05-06	2024-04-15	スペファームアーゲー	医薬製剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3426011A (en)	1967-02-13	1969-02-04	Corn Products Co	Cyclodextrins with anionic properties
EP0163836B1 (de)	1984-04-07	1988-10-12	Bayer Ag	Verfahren und Vorrichtung zur Herstellung von Granulaten
US4920214A (en)	1986-04-16	1990-04-24	American Maize-Products Company	Process for producing modified cyclodextrins
US5658894A (en)	1989-04-23	1997-08-19	The Trustees Of The University Of Pennsylvania	Compositions for inhibiting restenosis
DK0392608T3 (da)	1989-04-12	1995-11-20	Procter & Gamble	Faste konsumentproduktsammensætninger, der indeholder cyclodextrinkomplekser af lille partikelstørrelse
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) *	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1991018022A1 (en)	1990-05-21	1991-11-28	Toppan Printing Co., Ltd.	Cyclodextrin derivative
US5324718A (en)	1992-07-14	1994-06-28	Thorsteinn Loftsson	Cyclodextrin/drug complexation
US5472954A (en)	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
IL111184A (en)	1993-10-08	2000-08-13	Farmarc Nederland B V Of Cito	Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
FR2735136B1 (fr)	1995-06-08	1997-08-14	Roquette Freres	Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en)	1997-10-24	1999-08-10	Pitha; Josef	Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) *	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DK0889056T3 (da)	1997-07-01	2006-07-17	Pfizer Prod Inc	Process for making a cyclodextrin
JP2003522207A (ja)	1998-02-23	2003-07-22	サイクロプス・イーエイチエフ	高エネルギーシクロデキストリン複合体
MA25590A1 (fr)	1998-09-14	2002-12-31	Inhale Therapeutic Syst	Agent actif de delivraison de poudre seche
US6555139B2 (en)	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
TWI242015B (en)	1999-11-29	2005-10-21	Akzo Nobel Nv	6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AUPR272901A0 (en) *	2001-01-25	2001-02-22	Gainful Plan Limited	Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr)	2001-03-08	2003-05-23	Roquette Freres	Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
US7034013B2 (en)	2001-03-20	2006-04-25	Cydex, Inc.	Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030028014A1 (en)	2001-04-26	2003-02-06	Chris Sikorski	Agglomerated modified cyclodextrin and process for making same
DE10240698A1 (de) *	2002-09-04	2004-03-18	Symrise Gmbh & Co. Kg	Cyclodextrinpartikel
WO2005042584A2 (en)	2003-10-31	2005-05-12	The University Of Kansas	Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
BRPI0418276B8 (pt) *	2003-12-31	2021-05-25	Cydex Pharmaceuticals Inc	formulação líquida inalável compreeendendo budesonida
PL2708225T3 (pl)	2004-04-23	2019-07-31	Cydex Pharmaceuticals, Inc.	Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
WO2006011051A1 (en)	2004-07-22	2006-02-02	Pfizer Products Inc.	Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060128654A1 (en)	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en)	2004-12-23	2006-08-31	Olaf Reer	Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions

2005
- 2005-10-26 EP EP20120189690 patent/EP2581078B1/en not_active Expired - Lifetime
- 2005-10-26 EP EP20110161125 patent/EP2335707B1/en not_active Expired - Lifetime
- 2005-10-26 HU HUE15165737A patent/HUE035181T2/hu unknown
- 2005-10-26 SI SI200532159T patent/SI2952197T1/sl unknown
- 2005-10-26 EP EP20120189687 patent/EP2583668B1/en not_active Expired - Lifetime
- 2005-10-26 DK DK05856927T patent/DK1945228T4/da active
- 2005-10-26 PT PT05856927T patent/PT1945228E/pt unknown
- 2005-10-26 WO PCT/US2005/038933 patent/WO2007050075A1/en not_active Ceased
- 2005-10-26 ES ES11161125.7T patent/ES2542893T3/es not_active Expired - Lifetime
- 2005-10-26 AT AT05856927T patent/ATE504305T1/de active
- 2005-10-26 DK DK15165737.6T patent/DK2952197T3/en active
- 2005-10-26 PT PT121896872T patent/PT2583668E/pt unknown
- 2005-10-26 PT PT111611257T patent/PT2335707E/pt unknown
- 2005-10-26 ES ES15165737.6T patent/ES2634670T3/es not_active Expired - Lifetime
- 2005-10-26 PL PL11161125T patent/PL2335707T3/pl unknown
- 2005-10-26 CA CA2928065A patent/CA2928065C/en not_active Expired - Lifetime
- 2005-10-26 SI SI200531989T patent/SI2335707T1/sl unknown
- 2005-10-26 AU AU2005337613A patent/AU2005337613B2/en not_active Expired
- 2005-10-26 CN CN2005800524218A patent/CN101365459B/zh not_active Expired - Lifetime
- 2005-10-26 EP EP20050856927 patent/EP1945228B9/en not_active Expired - Lifetime
- 2005-10-26 JP JP2008537669A patent/JP5465432B2/ja not_active Expired - Lifetime
- 2005-10-26 ES ES12189687.2T patent/ES2526903T3/es not_active Expired - Lifetime
- 2005-10-26 HU HUE11161125A patent/HUE025315T2/en unknown
- 2005-10-26 PL PL12189687T patent/PL2583668T3/pl unknown
- 2005-10-26 BR BRPI0520654A patent/BRPI0520654B8/pt active IP Right Grant
- 2005-10-26 MX MX2017008827A patent/MX383536B/es unknown
- 2005-10-26 DK DK12189690T patent/DK2581078T3/en active
- 2005-10-26 LT LTEP15165737.6T patent/LT2952197T/lt unknown
- 2005-10-26 ES ES12189690.6T patent/ES2532374T3/es not_active Expired - Lifetime
- 2005-10-26 ES ES05856927.8T patent/ES2364491T5/es not_active Expired - Lifetime
- 2005-10-26 CA CA2632211A patent/CA2632211C/en not_active Expired - Lifetime
- 2005-10-26 PL PL15165737T patent/PL2952197T3/pl unknown
- 2005-10-26 DK DK11161125.7T patent/DK2335707T3/en active
- 2005-10-26 PL PL12189690T patent/PL2581078T3/pl unknown
- 2005-10-26 DK DK12189687T patent/DK2583668T3/en active
- 2005-10-26 PT PT12189690T patent/PT2581078E/pt unknown
- 2005-10-26 EP EP15165737.6A patent/EP2952197B1/en not_active Expired - Lifetime
- 2005-10-26 DE DE200560027415 patent/DE602005027415D1/de not_active Expired - Lifetime
- 2005-10-26 KR KR20087012541A patent/KR101152886B1/ko not_active Expired - Lifetime
- 2005-10-26 MX MX2013014698A patent/MX348982B/es unknown
- 2005-10-26 PT PT151657376T patent/PT2952197T/pt unknown
2008
- 2008-04-23 US US12/108,228 patent/US8049003B2/en active Active
- 2008-04-27 IL IL191081A patent/IL191081A/en active IP Right Grant
2015
- 2015-03-02 CY CY20151100214T patent/CY1116080T1/el unknown
- 2015-07-17 CY CY20151100626T patent/CY1116517T1/el unknown
2016
- 2016-02-15 IL IL244130A patent/IL244130B/en active IP Right Grant
2017
- 2017-07-13 CY CY20171100746T patent/CY1119471T1/el unknown
2019
- 2019-09-24 IL IL269619A patent/IL269619B/en active IP Right Grant

Also Published As

Publication number	Publication date
EP1945228A4 (en)	2010-04-07
EP2581078B1 (en)	2014-12-10
EP1945228B2 (en)	2014-11-05
PT1945228E (pt)	2011-07-13
JP5465432B2 (ja)	2014-04-09
EP2952197A1 (en)	2015-12-09
HK1184070A1 (en)	2014-01-17
CY1119471T1 (el)	2018-03-07
PT2335707E (pt)	2015-09-10
HK1184383A1 (en)	2014-01-24
IL269619B (en)	2020-07-30
ES2542893T3 (es)	2015-08-12
EP2581078A1 (en)	2013-04-17
IL191081A0 (en)	2009-08-03
EP2583668B1 (en)	2014-10-08
HUE025315T2 (en)	2016-02-29
CA2928065A1 (en)	2007-05-03
EP1945228B1 (en)	2011-04-06
KR20080063526A (ko)	2008-07-04
PL2583668T3 (pl)	2015-05-29
DK2952197T3 (en)	2017-08-07
EP2952197B1 (en)	2017-04-26
DK1945228T3 (da)	2011-07-25
MX348982B (es)	2017-07-06
PT2581078E (pt)	2015-03-10
CY1116080T1 (el)	2017-02-08
SI2952197T1 (sl)	2017-09-29
DK2583668T3 (en)	2015-01-19
US8049003B2 (en)	2011-11-01
IL191081A (en)	2016-03-31
BRPI0520654A2 (pt)	2009-05-19
PL2581078T3 (pl)	2015-07-31
KR101152886B1 (ko)	2012-07-09
EP2335707A1 (en)	2011-06-22
CN101365459A (zh)	2009-02-11
CA2632211A1 (en)	2007-05-03
LT2952197T (lt)	2017-08-25
ES2532374T3 (es)	2015-03-26
CN101365459B (zh)	2011-11-30
EP2583668A1 (en)	2013-04-24
IL244130B (en)	2020-06-30
CA2632211C (en)	2016-07-05
CA2928065C (en)	2019-10-15
DK2581078T3 (en)	2015-03-02
ES2364491T3 (es)	2011-09-05
HUE035181T2 (hu)	2018-05-02
EP1945228A1 (en)	2008-07-23
AU2005337613B2 (en)	2011-04-28
PT2952197T (pt)	2017-07-28
BRPI0520654B8 (pt)	2021-05-25
IL269619A (en)	2019-11-28
DE602005027415D1 (de)	2011-05-19
ES2526903T3 (es)	2015-01-16
ES2634670T3 (es)	2017-09-28
AU2005337613A1 (en)	2007-05-03
EP2335707B1 (en)	2015-05-06
JP2009513773A (ja)	2009-04-02
DK2335707T3 (en)	2015-08-10
SI2335707T1 (sl)	2015-09-30
BRPI0520654B1 (pt)	2020-08-11
HK1158978A1 (en)	2012-07-27
CY1116517T1 (el)	2017-03-15
EP1945228B9 (en)	2015-03-11
WO2007050075A1 (en)	2007-05-03
ES2364491T5 (es)	2015-02-19
MX383536B (es)	2025-03-14
PL2335707T3 (pl)	2015-10-30
PT2583668E (pt)	2015-01-05
HK1218509A1 (en)	2017-02-24
DK1945228T4 (da)	2015-01-12
ATE504305T1 (de)	2011-04-15
US20090011037A1 (en)	2009-01-08
IL244130A0 (en)	2016-04-21

Publication	Publication Date	Title
IL244130B (en)	2020-06-30	Formulations of sulfoalkyl ether cyclodextrin and methods for their preparation
EA200701442A1 (ru)	2008-02-28	Композиции наночастиц кандесартана
WO2007146491A3 (en)	2008-06-05	Flowable particulates
IL184111A0 (en)	2007-10-31	Prostaglandin-containing compositions and methods for enhancing the stability thereof
IL200846A0 (en)	2010-05-17	Oligomer-protease inhibitor conjugates, compositions comprising the same and uses thereof
WO2008057697A3 (en)	2008-08-07	Cross-linked polymer particles
WO2007106436A3 (en)	2007-11-22	Photoactive compounds and compositions and uses thereof
BRPI0909787A2 (pt)	2015-10-06	composição de moldagem termoplástica, usos da combinação de polieteraminas com óxidos amorfos, e de composições de moldagem trermoplásticas, fibra, folha ou moldagem, e, combinação dos componentes.
IL200847A0 (en)	2010-05-17	Oligomer-antihistamine inhibitor conjugates, compositions comprising the same and uses thereof
IL189473A0 (en)	2008-08-07	Aqueous anaesthetic compositions comprising propofol
WO2008112277A3 (en)	2008-11-20	Compositions and methods for treating cancer
PL1922128T3 (pl)	2012-08-31	Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
IL191567A0 (en)	2008-12-29	Clear and thickening aqueous compositions, the use thereof in acidic aqueous formulations, and the resulting formulations
EA200800099A1 (ru)	2008-06-30	Композиции наночастиц мегестрола
WO2006119494A3 (en)	2007-04-26	Acute myelogenous leukemia biomarkers
MX2021006926A (es)	2022-12-12	Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
WO2005013955A3 (en)	2005-04-28	Topical composition comprising terbinafine and hydrocortisone
TW200712129A (en)	2007-04-01	Silicone material having outstanding viscosity stability
WO2006023882A3 (en)	2006-12-21	Anti-perspirant compositions with improved properties
UA29280U (en)	2008-01-10	Nanometal aquachelate
GEP20104890B (en)	2010-02-10	Polymer concrete